Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study
International Journal of Breast Cancer · 2025-01 · 2025 (1)
DOI: 10.1155/ijbc/5597051 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Breast Cancer, online erschienen am 04.11.2025. Verfasst von Thiti Susiriwatananont und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
HER2‐low status is a predictive factor for novel anti‐HER2 therapies in metastatic hormone receptor–positive breast cancer (HR+ MBC). However, its impact on endocrine therapy outcomes remains uncertain. We aimed to explore the effect of HER2‐low and HER2‐zero status in HR+ MBC patients treated with first‐line aromatase inhibitors (AIs) with or without CDK4/6 inhibitors (CDK4/6i).
Methods
We retrospectively reviewed postmenopausal women with HR+ MBC treated with first‐line AI ± CDK4/6i between January 1, 2017, and December 31, 2022, from six tertiary hospitals in Thailand. HER2‐low was defined as HER2 IHC 1+ or IHC 2+ with ISH‐negative. Progression‐free survival (PFS) and overall survival (OS) were compared in unadjusted and adjusted cohorts using stabilized inverse probability of treatment weighting (sIPTW), adjusting for age, ECOG performance status, de novo metastasis, endocrine sensitivity, visceral metastasis, number of metastatic sites, and treatment year. Interaction analyses were performed to assess effect modification by HER2 status and other clinical subgroups.
Results
Among 504 patients, 219 (43.5%) were HER2‐low, and 285 (56.5%) were HER2‐zero. Median follow‐up was 31 months (IQR 19–47). CDK4/6i + AI was administered to 52.5% of HER2‐low and 43.9% of HER2‐zero patients. After sIPTW adjustment, CDK4/6i + AI prolonged median PFS to 22.1 months compared with 21.5 months for AI alone in the HER2‐low cohort (HR = 0.80, 95% CI 0.54–1.18; p = 0.26) and to 20.1 months compared with 13.5 months in the HER2‐zero cohort (HR = 0.65, 95% CI 0.45–0.93; p = 0.02). Median OS was 49.3 months with CDK4/6i + AI versus 48.4 months with AI alone in HER2‐low (HR = 0.81, 95% CI 0.48–1.36; p = 0.43) and 45.8 versus 42.3 months in HER2‐zero (HR = 0.85, 95% CI 0.43–1.05; p = 0.52). Subgroup analyses showed consistent benefit of CDK4/6i + AI across most clinical categories. The interaction test for treatment × HER2 status was not significant (HR = 1.21, 95% CI 0.74–1.98; p = 0.44), indicating no effect modification by HER2‐low status.
Conclusions
HER2‐low status was not associated with prognosis or predictive value for CDK4/6i efficacy, supporting CDK4/6i + AI as the standard first‐line therapy irrespective of HER2 expression level.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand.
- Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Department of Medical Oncology, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.
- Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
- Division of Oncology, Department of Internal Medicine, Sawanpracharak Medical Education Center, in Affiliation With Faculty of Medicine, Praboromrajchanok Institute, Nakhon Sawan, Thailand.
ORCID-Profile: Thiti Susiriwatananont, Concord Wongkraisri, Thanate Dajsakdipon, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Suthinee Ithimakin, Thitiya Dejthevaporn, Napa Parinyanitikul
Zitieren
APA
Susiriwatananont, T., Wongkraisri, C., Dajsakdipon, T., Supavavej, A., Dechaphunkul, A., Sunpaweravong, P., Neesanun, S., Ithimakin, S., Dejthevaporn, T., Parinyanitikul, N., & TSCO Breast Oncology Group (2025). Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study. International Journal of Breast Cancer, 2025(1). https://doi.org/10.1155/ijbc/5597051
Vancouver
Susiriwatananont T, Wongkraisri C, Dajsakdipon T, Supavavej A, Dechaphunkul A, Sunpaweravong P, et al. Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study. International Journal of Breast Cancer. 2025;2025(1). doi:10.1155/ijbc/5597051
BibTeX
@article{Susiriwatananont2025,
author = {Susiriwatananont, Thiti and Wongkraisri, Concord and Dajsakdipon, Thanate and Supavavej, Archara and Dechaphunkul, Arunee and Sunpaweravong, Patrapim and Neesanun, Sunee and Ithimakin, Suthinee and Dejthevaporn, Thitiya and Parinyanitikul, Napa and TSCO Breast Oncology Group, TSCO Breast Oncology Group},
title = {Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study},
journal = {International Journal of Breast Cancer},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/ijbc/5597051}
}
EUVIMED